IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.
about
IgG4 Characteristics and Functions in Cancer ImmunityHuman IgG4: a structural perspectiveGlycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical reviewMucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal ChallengeEngineering Hydrophobic Protein–Carbohydrate Interactions to Fine-Tune Monoclonal AntibodiesImmune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodiesFc gamma receptors: glycobiology and therapeutic prospectsDouble knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCCA prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancyB cells and the humoral response in melanoma: The overlooked players of the tumor microenvironmentHinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys.New paradigms for functional HIV-specific nonneutralizing antibodiesClearance of human IgG1-sensitised red blood cells in vivo in humans relates to the in vitro properties of antibodies from alternative cell lines.Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newbornExploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding.Lepidopteran cells, an alternative for the production of recombinant antibodies?Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors.The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.Lectin-based analysis of fucosylated glycoproteins of human skim milk during 47 days of lactationProtein glycosylation in diverse cell systems: implications for modification and analysis of recombinant proteins.Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy.Antibody therapeutics: isotype and glycoform selection.Antibodies and their receptors: different potential roles in mucosal defense.Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies.Antibody-dependent CD56+ T cell responses are functionally impaired in long-term HIV-1 infection.Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDCAglycosylated antibodies and the methods of making and using them: WO2008030564.Production of therapeutic antibodies with controlled fucosylation.Optimizing therapeutic antibody function: progress with Fc domain engineering.Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach.CMV-encoded Fcγ receptors: modulators at the interface of innate and adaptive immunity.New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics.Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.Production, Characterization, and Biological Evaluation of Well-Defined IgG1 Fc Glycoforms as a Model System for Biosimilarity Analysis.Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®.Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile.Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro.IgG Fc variant cross-reactivity between human and rhesus macaque FcγRs.Assessment of disulfide and hinge modifications in monoclonal antibodies
P2860
Q26770244-692145E0-5E48-426E-8902-1E1CDF96A64EQ26779758-3A2E0377-99E4-445E-87B9-9D0B8870E229Q26782025-6DC903A8-C2BF-475D-A8A4-3470BBB0738CQ27318151-D408D4EE-E513-4B23-8060-E7B145970037Q27678524-EB696522-88CB-450F-96F0-3228FF665A2CQ28069362-FF29BE0A-9A66-4A93-B478-B4AB4DB56D63Q28076303-1AA79FD6-1DF2-4209-8C06-CD1381A8A407Q33307815-B9A3D4AF-EC0D-41A2-A590-B8F9D22D8518Q33411528-74D4BE75-40AB-431F-93E5-99A5FB788073Q33632113-460EC8D9-1620-4B70-A48F-6DE3769BB647Q33681420-F3BCB177-5B96-40E4-B83C-0C8F86C2E7EEQ33900595-B55F090A-8A2F-4B9A-8876-E0F06CFAE85FQ34323394-AB8B2EF0-311E-426D-B7AF-7BA6D20CDBFBQ34803358-A2D60DC7-E2F1-41AC-9C66-A960D36129C2Q34869927-4CD2D92C-38A7-46E4-8255-4FE6EB77CBC6Q35031336-6013181C-671B-4BD4-BE44-4FDA972ED09DQ35969904-2EE4119B-FE8B-4EC6-A30A-8436ED5E96CFQ36131665-C0410B85-DF01-48B3-AD27-46E39500C2B4Q36213158-9E4E5D65-3FB4-45B2-9B8C-9CD41F854E20Q36297326-CBD3A720-8B7A-4BA2-B816-05B9CB0584F9Q36505675-3CC3AD10-13FC-4289-A1E9-4BD4C91DA6DAQ36691991-28CA988D-C155-432B-ADE6-B9F1FB7B95C6Q36922260-EDD2E21C-2576-4EC7-856B-7269FB709C8DQ37015487-F5A4881F-ABBB-4294-84F0-9B6D34EC21DFQ37323537-D345A93A-12B5-434E-95AC-8002C3DF8AB9Q37396363-9C79E388-6C66-40ED-A5DC-076EA40F9140Q37403194-1C1160C8-7FE8-4C35-86D6-2300CD9564E3Q37481248-3F3F632A-5C76-4CFD-A78A-738482C6AA7FQ37672128-23344309-7050-4265-A24E-F802F763E385Q37804830-B36BC0BF-DB94-4000-AECF-04FFC5A8ED9AQ37999739-C0AF1797-959D-4D97-A0E6-62916A43D658Q38257496-C125D3FB-AA6C-4A41-80E9-A81D2E211161Q38289992-8473638E-4CCA-400C-81F4-AE7C3974B394Q38308978-3FF3A936-5FA5-4F42-8C4F-89456BBA5195Q38408253-154C14DF-206D-487E-B427-FDEE21EEA756Q38699354-49E17601-66EF-4304-93D9-6B871B09D77EQ38752663-0FE4C4F2-569C-46C1-A697-B644FD80138CQ38808291-AD8DA708-331F-4E68-BAFB-08C652D1E550Q39038535-168CC52C-0608-49E4-93B2-3EB31484D1EFQ39041113-60E30EBE-BE7A-46E9-ACFF-DE8691835E2E
P2860
IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
IgG subclass-independent impro ...... sn297-linked oligosaccharides.
@en
type
label
IgG subclass-independent impro ...... sn297-linked oligosaccharides.
@en
prefLabel
IgG subclass-independent impro ...... sn297-linked oligosaccharides.
@en
P2093
P921
P1476
IgG subclass-independent impro ...... sn297-linked oligosaccharides.
@en
P2093
Akito Natsume
Aya Uehara
Kazuhisa Uchida
Kenya Shitara
Masako Wakitani
Mitsuo Satoh
Rinpei Niwa
Shigeru Iida
P304
P356
10.1016/J.JIM.2005.08.009
P577
2005-09-22T00:00:00Z